Breast Cancer

New options for advanced breast cancer listed on PBS

Ribociclib (Kisqali) in combination with fulvestrant has been PBS-listed for the treatment of patients with HR-positive, HER2-negative unresectable advanced or metastatic breast cancer. Pivotal studies included the MONALEESA-3 trial which showed overall survival with the CDK4/6 inhibitor plus fulvestrant was significantly longer than with fulvestrant alone in this group of patients (OS at 42 months ...

Already a member?

Login to keep reading.

© 2021 the limbic